Key Highlights

  • Four mid-cap healthcare and consumer stocks gained 34.93% to 53.54% over one month in published market data as of October 28, 2026: FIGS at 53.54%, Kodiak Sciences at 52.22%, Wingstop at 38.64% and Iovance at 34.93%.
  • Kodiak Sciences (NASDAQ:KOD) reported Phase 3 wet AMD results on September 28, 2026 and plans a biologics license application in the fourth quarter, while Iovance raised 2026 revenue guidance to USD 410 million to USD 420 million on September 29.
  • Wingstop (NASDAQ:WING) rose 12.03% on October 28 after third quarter results showed domestic same store sales down 5.4% and revenue of USD 185.1 million. FIGS rose with no new company release found.
  • Iovance Biotherapeutics (NASDAQ:IOVA) holds about USD 243 million of cash and investments and Kodiak Sciences about USD 126 million, so funding and launch execution are the shared risks for the two healthcare names.

Kodiak Sciences (NASDAQ:KOD): Up 52.22% on Phase 3 Data

Kodiak Sciences (NASDAQ:KOD) rose 52.22% in a month to USD 93.93 after Phase 3 DAYBREAK wet AMD results on September 28, 2026, with a biologics license application planned for the fourth quarter. On September 28, 2026, the company reported topline results from the DAYBREAK Phase 3 study in wet AMD. Zenkuda (tarcocimab tedromer) met its primary endpoint with a p-value of 0.0007, and tabirafusp-ted met its visual acuity primary endpoint with a p-value of 0.0036 and a key anatomical secondary endpoint with a p-value below 0.0001. About 54% of Zenkuda patients reached a six-month dosing interval under a strict treat-to-dryness standard. Published analyst actions followed: LifeSci Capital to USD 145, Jefferies to USD 112, UBS to USD 120, H.C. Wainwright to USD 126 and Goldman Sachs to USD 103 with a Neutral rating. The company plans to file a biologics license application for Zenkuda in the fourth quarter of 2026, covering wet AMD, diabetic retinopathy and retinal vein occlusion, and the topline readout of the PEAK study of KSI-101 is expected in December 2026. Kodiak Sciences (NASDAQ:KOD) is up 129.55% over three months and 236.55% year to date. Kodiak has no commercial product or revenue and reported about USD 126 million of cash at the end of the second quarter, which management says supports operations into 2027, so an equity raise, partnership or royalty deal is likely.

Iovance Biotherapeutics (NASDAQ:IOVA): Up 34.93% on a Guidance Raise

Iovance Biotherapeutics (NASDAQ:IOVA) rose 34.93% in a month to USD 14.68 after raising 2026 revenue guidance on September 29, 2026 and winning a Goldman Sachs Buy rating. On September 29, 2026 the company raised its full-year revenue forecast by USD 55 million at the midpoint, implying nearly 60% annual growth. It cited rising patient demand for Amtagvi and a manufacturing schedule that gives strong visibility into the third and fourth quarters. Iovance Biotherapeutics (NASDAQ:IOVA) has gained 224.06% over three months and 535.50% over one year. Goldman Sachs resumed coverage with a Buy rating and a USD 15 target on the view that launch-related operational and logistical challenges are easing and should support better gross margins. The company is running the TILVANCE-301 Phase 3 study of lifileucel with Keytruda in first-line advanced melanoma and has registrational programs in non-small cell lung cancer and endometrial cancer. A rise of 428.06% year to date leaves the stock vulnerable to profit-taking, and the price is close to the only target cited. The launch is still scaling, cash of about USD 243 million must fund a large clinical program and an interim chief executive adds leadership uncertainty.

Wingstop (NASDAQ:WING): Up 38.64% Around Third Quarter Results

Wingstop (NASDAQ:WING) rose 38.64% in a month to USD 138.38, including 12.03% on October 28, 2026 after third quarter results, though same store sales fell 5.4%. For the quarter ended September 26, 2026, system-wide sales rose 6.0% to about USD 1.4 billion while domestic same store sales fell 5.4%. Domestic average unit volume was USD 1.848 million against USD 2.061 million a year earlier. Revenue was USD 185.1 million, net income USD 29.1 million, adjusted EBITDA USD 64.0 million and adjusted earnings USD 1.08 per share. The month's gain implies a price near USD 99.81 a month ago, simple arithmetic, so the rebound began before the report and a further 12.03% on the day looks like relief. Same store sales were weak and revenue missed estimates, so the reaction suggests investors had expected worse. Wingstop (NASDAQ:WING) is flat over three months at down 0.38% and up 8.24% over one week. The quarterly dividend is USD 0.33 per share, payable December 4, 2026 to holders of record on November 13. In the quarter the company repurchased 190,688 shares at an average of USD 131.12 and has USD 288.4 million of buyback authorization left.

FIGS (NYSE:FIGS): Up 53.54% Without New News

FIGS (NYSE:FIGS) rose 53.54% in a month to USD 20.38 without new company news, resting on August results and a raised outlook, with the next report due November 5, 2026. The last company report came on August 6, 2026. Revenue of USD 196.6 million rose 28.8%, the third straight quarter above 25%, and earnings were USD 0.15 per share. Non-scrubwear revenue rose 40.3% to USD 35.4 million and international revenue rose 67% to USD 37.9 million. The month's gain of 53.54% implies a price near USD 13.27 a month ago, simple arithmetic. In that time the company issued no new release that this review could find, so the move reflects the August results, rising expectations and momentum. FIGS (NYSE:FIGS) has gained 92.22% over three months and 78.88% year to date. Consensus 2027 earnings growth is only about 6%, set against a valuation near 55 times forward earnings, a gap that leaves little room for a miss. The next report is scheduled for November 5, 2026, and a beat with stronger guidance would probably be needed to hold the rally.

Where Things Stand

The answer is that company data explain three of the four gains and an earnings-driven rally explains the fourth. Kodiak Sciences (NASDAQ:KOD) must file and win approval. Iovance Biotherapeutics (NASDAQ:IOVA) must deliver on a raised revenue range. Wingstop (NASDAQ:WING) remains down 42.75% year to date. FIGS (NYSE:FIGS) trades about 9% above its average analyst target. Each can reverse if the next report disappoints. Watch FIGS on November 5 and the early November reports.